三阴性乳腺癌在免疫治疗中的研究进展  

Research progress of triple negative breast cancer in immunotherapy

作　　者：裴晓婵 丘平[2] PEI Xiaochan;QIU Ping(Graduate School of Guangxi University of Traditional Chinese Medicine,Nanning,Guangxi,530000,China;Department of Breast,Guilin Traditional Chinese Medicine Hospital,Guilin,Guangxi,541000,China)

机构地区：[1]广西中医药大学研究生院,广西南宁530000 [2]桂林市中医医院乳腺科,广西桂林541000

出　　处：《当代医学》2024年第10期8-12,共5页Contemporary Medicine

摘　　要：三阴性乳腺癌(TNBC)是指病理染色报告中,雌激素受体(ER)和孕酮受体(PR)及人表皮生长因子受体2(HER-2)均为阴性的乳腺癌亚型,是目前乳腺癌治疗中最棘手、进展最快、死亡率及复发率最高的亚型。TNBC区别于其他亚型乳腺癌的主要特征在于其无明确靶点,无法选择靶点治疗。目前国际指南对于TNBC主要以化学治疗为主,但随着医疗技术进步,越来越多的免疫治疗被证实在TNBC的直接和间接治疗中起到关键作用。本文就近年来免疫治疗TNBC的研究进展进行综合论述。Triple negative breast cancer(TNBC)refers to the subtype of breast cancer with negative estrogen receptor(ER),progesterone receptor(PR)and human epidermal-growth-factor receptor 2(HER-2)in the pathological staining report,it is the most difficult,fastest progress,highest mortality and recurrence rate in the treatment of breast cancer.TNBC is different from other subtypes of breast cancer,it has no clear target and cannot select target therapy.At present,the international guidelines for TNBC are mainly based on chemotherapy,however,with the progress of medical technology,more and more immunotherapy has been proved to play a key role in the direct and indirect treatment of TNBC.This article reviews the research progress of immunotherapy in TNBC in recent years.

关 键 词：免疫治疗 三阴性乳腺癌 程序性死亡受体-1 程序性死亡受体-配体1 免疫激活剂 疫苗 

分 类 号：R737.9[医药卫生—肿瘤]